Arcus Biosciences enters the stretch before its June 11 earnings report carrying two conflicting signals: a fresh clinical collaboration with Bristol Myers Squibb that validates its HIF-2α inhibitor, casdatifan, and a short base that has quietly rebuilt 8% in a single week.
Short sellers have added meaningfully to their positions. Short interest climbed to roughly 9% of the free float by June 2 — up 8% on the week and now running at the high end of the past six weeks. The rebuild accelerated from May 26, when shorts jumped from around 10.3 million shares to over 11 million across just a few sessions. Despite that build, the lending market remains wide open. Availability stands at 1,675% — more than sixteen times the shares already borrowed — and the cost to borrow is barely above zero at 0.44%. These are not the conditions of a squeeze-threatened stock; they are the conditions of a stock where additional short supply is abundant and demand is still building.
Options positioning, by contrast, looks almost indifferent. The put/call ratio of 0.41 sits fractionally below its 20-day average of 0.42, with a z-score near flat. That is a notably muted options read for a name heading into earnings in eight days. The PCR has drifted lower from the 0.47 range seen through early May, suggesting call buyers rather than put buyers have been more active — an odd setup given the short rebuild.
The story that cuts through this divergence is the BMS deal announced Wednesday. Arcus will supply casdatifan, its investigational HIF-2α inhibitor, for a clinical trial evaluating the drug in combination with BMS's PD-L1/VEGF-A bispecific in renal cell carcinoma. The announcement carries a newsImportance score of 10 from ORTEX — the maximum. It lands directly on the bear case: bears have worried about competition from Merck and others in the HIF-2α space and declining RCC market dynamics. A partnership with BMS to test a novel combination directly addresses the "what differentiates casdatifan" question that has weighed on the stock. The stock was down 4.7% on June 2 before the deal was disclosed, and the next print — June 11 — will be watched for any early data or commercial colour.
The analyst community has been broadly constructive, though with meaningful dispersion on target prices. Goldman Sachs raised its target to $34 in early May, maintaining its Buy. Truist assumed coverage with a Buy and a $35 target in mid-May. Morgan Stanley held at Equal-Weight and lifted its target to $22 — the outlier on the Street, with a target well below the current $24.47 price and a long way from the consensus mean of $34.82. The gap between the Morgan Stanley view and the rest of the Street is wide enough to anchor the bear case: at current levels, any analyst who moves toward the MS framework would put the stock underwater relative to the $22 target. Goldman and Truist's targets imply 39–43% upside from here, which is the bull camp's argument in compact form.
The two most recent prior earnings reactions were muted. The May 2026 report produced essentially flat movement on day one and a modest 4.4% five-day drift lower. The February 2026 print was more interesting: the stock dropped 3.2% the next day but then recovered 12.3% over the following week, suggesting the market found value in the initial sell-off. With the BMS collaboration announced two days before the June 11 date, the upcoming print is therefore less about the pipeline narrative — BMS has already provided a third-party endorsement — and more about whether the financials and any casdatifan clinical updates justify the gap between Morgan Stanley's $22 and the consensus $35.
See the live data behind this article on ORTEX.
Open RCUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
